Philina Lee

AdvanCell Pty Ltd, a clinical-stage radiopharmaceutical company advancing targeted alpha therapies for cancer, has appointed Philina Lee, PhD, as Chief Executive Officer and member of the Board of Directors. 

Dr. Lee will lead AdvanCell’s expansion in the United States and drive the company’s next phase of global growth, strengthening clinical development, manufacturing capabilities, and strategic partnerships. She will assume the role on January 1, 2026, and will be based at AdvanCell’s new US headquarters near Boston/Cambridge, Massachusetts.

Dr. Lee joins AdvanCell from Blueprint Medicines Corporation, which was recently acquired by Sanofi for approximately US$9.5 billion. At Blueprint, she served as Chief Commercial Officer, where she played a key role in shaping corporate strategy and building robust commercial infrastructure across oncology and mast cell disorders. Her experience also includes serving on the Board of Directors of Fusion Pharmaceuticals Inc., a radiopharmaceutical company, and holding senior leadership roles at Algeta ASA, a pioneer in alpha therapies. At Algeta, she contributed to the successful US launch of Xofigo® (radium-223 dichloride), the first and only approved alpha therapy, in collaboration with Bayer AG.

Dr. Lee holds a Bachelor of Science in Biochemistry from the University of Alberta and a PhD in Cell Biology from the Massachusetts Institute of Technology.

She succeeds founder and long-standing CEO Andrew Adamovich, who will continue as Managing Director, Australia, and remain on AdvanCell’s Board of Directors. The Board expressed its appreciation for Mr. Adamovich’s leadership in building AdvanCell from an early-stage concept into a vertically integrated, clinical-stage radiopharmaceutical company with manufacturing operations in Australia, an expanding US presence, and strong partnerships across isotope supply, research, and clinical translation.